Because insurers typically will not pay for unproven stem cell interventions, patients seeking these services must purchase them out-of-pocket or use alternative funding mechanisms such as crowdfunding (ie, using online social networks to solicit donations).
rect-to-consumer (DTC) marketing of stem cell interventions. After receiving an exemption from ethics review from Simon Fraser University's research ethics board, we searched from August 2017 to December 2017 for mentions of each of these businesses on the crowdfunding platforms GoFundMe and YouCaring. These websites are the 2 largest charitable crowdfunding platforms by money raised as measured by crowdfunding.com. An external search engine was used to verify results and identify additional campaigns on these platforms. For each campaign, we extracted data on the amount of funding requested and pledged, number of donors, and shares on Facebook and Twitter. We identified all statements about the perceived risks and efficacy of these interventions. Risk statements were evaluated as claiming medium/high or low/no risks compared with alternative treatments. Efficacy statements were classified as (1) definitive or certain about efficacy; (2) optimistic or hopeful about efficacy; (3) definitive and optimistic; or (4) no efficacy statements. Two authors (J.S. and L.T.) independently classified these statements, with the third author resolving disagreements.
Results | As of December 3, 2017, our search identified 408 campaigns (GoFundMe = 358; YouCaring = 50) seeking donations for stem cell interventions advertised by 50 individual businesses. These campaigns requested $7 439 308 and received pledges for $1 450 011 from 13 050 donors. The campaigns were shared 111 044 times on social media. Two campaigns were duplicated across platforms but shared separately on social media. Of the 408 campaigns, 178 (43.6%) made statements that were definitive or certain about the intervention's efficacy, 124 (30.4%) made statements optimistic or hopeful about efficacy, 63 (15.4%) made statements of both kinds, and 43 (10.5%) did not make efficacy claims. All mentions of risks (n = 36) claimed the intervention had low/no risks compared with alternative treatments.
Discussion | Crowdfunding campaigns for unproven stem cellbased interventions underemphasize risks and exaggerate the efficacy of these interventions. These findings suggest that medical crowdfunding campaigns convey potentially misleading messages about stem cell-based interventions. These claims may be especially powerful when embedded within compelling personal narratives. The situation parallels that of DTC marketing of unproven stem cell-based interventions, which has been shown to make hyperbolic claims about efficacy and minimize risks associated with their use. [3] [4] [5] Although many publications examine DTC marketing by stem cell clinics, there is little research examining how individuals make sense of and act on such advertising claims. These findings suggest that individuals interested in purchasing unproven stem cell interventions may reflect DTC marketing messages in crowdfunding campaigns, thus potentially helping propagate them.
Although GoFundMe does not publish its total number of health-related campaigns, YouCaring reported (https://www .youcaring.com/fundraisers/medical-expenses) 62 739 campaigns on February 26, 2018; thus, campaigns for stem cell therapies represent a small percentage of their overall campaigns.
A limitation of the study is that only campaigns referencing 1 of the 351 businesses and on 2 crowdfunding platforms were included. Thus, these results likely underestimate the total number of crowdfunding campaigns for stem cell interventions advertised by these businesses.
Physicians providing care to patients crowdfunding for unproven stem cell-based interventions face difficult questions concerning how best to interact with these individuals. 6 They should be aware of the potential for crowdfunding campaigns to help spread inaccurate information. The interests of both patients and the public suggest a role for clinicians in actively combating this misinformation by challenging problematic DTC marketing messages. 
COMMENT & RESPONSE Antibiotic Prophylaxis for Removal of Lower Leg Orthopedic Implants
To the Editor In a randomized clinical trial of 477 patients from 19 centers in the Netherlands undergoing removal of orthopedic hardware from below the knee, patients were randomized to preoperative cefazolin or placebo (saline) with a resultant overall infection rate of 14% and no difference between groups. The authors concluded that preoperative antibiotics for these surgeries did not reduce the risk of surgical site infections (SSIs).
1
A 14% SSI rate is higher than the rate reported in most previous studies.
2,3 However, Sanderson et al 4 reported an infection rate of 14.3% for removal of hardware without prophylactic antibiotics, similar to the results of the current study. Dr Backes and colleagues reported on both superficial and deep infections. Most infections were superficial, but only 1 (0.4%) deep infection occurred in the cefazolin group vs 7 (2.9%) in the saline group. Although the difference was not statistically significant, this study was not powered to analyze deep infections. Superficial infection criteria could have been as simple as the surgeon diagnosing it, whereas the diagnosis of deep infection required purulent drainage from the incision or opening of an incision with a positive microbiology test and symptoms, or evidence of deep abscess. Starting antibiotics also classified a patient as infected without further objective data. We wonder whether the criteria for characterizing a superficial infection were not stringent enough, especially given possible variations between 19 centers. Is it possible that some patients classified as having a superficial infection did not really have an SSI? The authors used the US Centers for Disease Control and Prevention (CDC) criteria for superficial and deep infections, 5 in which local cellulitis, stitch abscesses, and pin site infections are not considered SSIs. Of 58 patients in the superficial infection group, only 2 had surgery to address it, and 9 were managed without antibiotics, which would argue against a true SSI.
The skin is a well-known carrier of bacteria, and superficial swabs often lead to polymicrobial culture results or contaminates. eTable 1 in the Supplement in the article showed numerous different culture growths in the superficial SSI group, consistent with superficial and possibly contaminated skin swabs.
